FDA approves Wegovy GLP-1 pill, pushing weight-loss drugs into new era

Dec 23, 2025 at 07:30 AM CST

A significant breakthrough in the weight-loss medication market: the FDA has approved the first GLP-1 pill for obesity treatment. — Image credit: Michael Siluk/UCG/Universal Images Group via Getty Images

This recording was made using enhanced software.

Summary

FDA approval

The FDA has approved the first GLP-1 pill for obesity treatment, manufactured by Novo Nordisk. The pill is scheduled for release in early 2026 and will be available through pharmacies and healthcare providers.

Medication pricing

Novo Nordisk announced the daily 1.5-milligram pill will cost about $149 per month, which is lower than many injectable alternatives, according to the company.

Drug effectiveness

According to Novo Nordisk, the pill contains the same active ingredient as Wegovy, semaglutide, and showed an average weight loss of 16.6% in clinical trials. The company claims it also helps with long-term weight reduction and lowers the risk of major adverse cardiovascular events.

Full story

A significant breakthrough in the weight-loss medication market: the FDA has approved the first GLP-1 pill for obesity treatment. Manufactured by Novo Nordisk, the company behind Wegovy, this drug is scheduled for release in early 2026.

It will be accessible via pharmacies and healthcare providers.

Novo Nordisk announced that the daily 1.5-milligram pill will be priced at approximately $149 per month. The price is notably lower than many injectable alternatives.

QR code for SAN app download

Download the SAN app today to stay up-to-date with Unbiased. Straight Facts™.

Point phone camera here

How it works

The pill contains the same active ingredient as Wegovy — semaglutide — which mimics a hormone in the body that reduces appetite and increases feelings of fullness.

According to Novo Nordisk, the pill showed a mean weight loss of 16.6% during trials, and works “to reduce excess body weight and maintain weight reduction long-term and to reduce the risk of major adverse cardiovascular events.”

The future of weight loss drugs

Health experts suggest that the pill could unlock access to a new group of patients, particularly those interested in GLP-1 benefits but hesitant about injections. CNBC reported that roughly one in eight adults currently uses a GLP-1 medication for weight management or health conditions such as diabetes.

Analysts project that the weight-loss drug market may hit $100 billion in the next few years. Competition is intensifying quickly, with Eli Lilly, the producer of Zepbound, poised to launch its own GLP-1 weight-loss pill soon.

Both Eli Lilly and Novo Nordisk previously reached a deal with the Trump administration to offer GLP-1 pills through Trump Rx, a new platform expected to launch in the new year.

The site allows those without insurance to buy drugs directly from manufacturers.

Julia Marshall is a morning digital producer at Straight Arrow News. Thanks to her extensive newsroom experience, Julia has a keen eye for news and extensive experience in writing and editing content across all topics and platforms.

Tags: GLP-1, Weight Loss

Speaker 0 00:00:02 A major breakthrough in the weight loss drug boom. The FDA has approved the first ever GLP one pill to treat obesity. The drug is made by Novo Nordisk, the maker of Wegovy, and is expected to hit the market in early 2026. It will be available through pharmacies and health providers. Nova Nordisk says the daily 1.5 milligram pill will cost about $149 a month, significantly less than many injectable options. The company has already struck a deal with the Trump administration to offer the pill through Trump rx a new platform expected to launch in the new year. The pill uses the same active ingredient as Wegovy Semaglutide, which mimics a hormone in the body that reduces appetite and increases feelings of fullness. Health experts say the pill could open the door to a whole new group of patients, especially people who want the benefits of GLP ones, but don’t want injections. According to CNBC, about one in eight adults is now taking a GLP one drug for weight loss or conditions like diabetes analysts estimate the weight loss drug market could reach $100 billion in the coming years, and competition is coming fast. Eli Lilly, the maker of Zep Bound, is also expected to release its own GLP one weight loss pill sometime soon.

Why this story matters

The approval of the first oral GLP-1 weight loss pill by the Food and Drug Administration introduces a new treatment option for obesity, potentially expanding patient access and setting the stage for broader changes in obesity care and pharmaceutical competition.

Expanded access

Oral medications may reach patients who avoid injectables due to cost, insurance, or fear of needles, according to multiple sources, making obesity treatment more accessible for more people.

Clinical effectiveness

Clinical trials showed the pill can deliver similar average weight loss as injectable formulations, with Novo Nordisk reporting up to 16.6% weight loss, though real-world results remain to be seen, as noted by experts in The New York Times and other outlets.

Market competition

The approval strengthens Novo Nordisk's position in a rapidly growing weight-loss drug market, with Eli Lilly and other manufacturers racing to introduce their own pills and potential for significant shifts in drug pricing and distribution.

Get the big picture

Synthesized coverage insights across 235 media outlets

Context corner

GLP-1 drugs were originally developed for diabetes and only recently became widely used for obesity, leading to a shift in both the medical and cultural landscape concerning chronic weight management.

Oppo research

Some experts caution that the pill’s strict dosage schedule may affect real-world effectiveness and note that oral GLP-1s may not achieve the same weight loss as newer injectable options. Cost and insurance coverage remain hurdles.

Policy impact

FDA approval broadens potential patient pools and may pressure insurers to consider coverage for oral obesity drugs but policy changes regarding Medicare and other programs are still in flux.

Politics

1 hr ago

2 min read

Trump deletes racist video depicting Obamas as apes after backlash
U.S.

6 hrs ago

12 min read

$50k reward in Guthrie search with no suspect; Trump launches Rx drug site
U.S.

16 hrs ago

4 min read

Law enforcement fighting online rumor mill in Nancy Guthrie investigation
U.S.

18 hrs ago

3 min read

Man charged with sending ‘imposter’ ransom note to Nancy Guthrie’s family

Sources

CNN
Novo Nordisk

Bias comparison

Media outlets on the left frame the oral weight-loss drug as a "crucial step" ushering in a "new era" for the "blockbuster" market, emphasizing its potential for "reducing costs" to expand access, yet de-emphasizing specific efficacy data.
Media outlets in the center balance these, noting the drug's "leg up" in the market and its role in "widening access" to address the "burgeoning global obesity crisis," even mentioning unspecified "drawbacks.
Media outlets on the right highlight the pill as a "more palatable option" for patients uncomfortable with needles, focusing on individual preference and market expansion, while detailing the 16.6% weight loss figure.

Report an issue with this comparison

Media landscape

Click on bars to see headlines

231 total sources

Key points from the Left

The US Food and Drug Administration approved Novo Nordisk's Wegovy pill for weight loss, providing an oral option in a class of drugs that includes the injectable Wegovy and Ozempic, which mimic the hormone GLP-1.
The Wegovy pill shows similar weight loss results to the injectable version, with an average of 16.6% weight loss over 64 weeks in trial participants.
This pill, priced at $149 for the starting dose, aims to provide an alternative for patients who prefer not to use injections.
Experts express cautious optimism about the Wegovy pill, noting convenience for patients but warning about adherence to the strict dosage schedule.

Report an issue with this summary

Key points from the Center

On Dec. 22, 2025 the U.S. Food and Drug Administration approved a pill version of Wegovy, Novo Nordisk A/S's first oral GLP-1 therapy cleared for weight management in the United States.
In the 64-week OASIS 4 trial, 307 adult participants randomized to oral semaglutide 25 mg showed mean weight loss of about 17% when treatment was adhered to.
Among trial participants, 76% achieved at least 5% weight loss; a 1.5 mg starting dose will be available in early January for $149 per month, and production is underway at Novo Nordisk North Carolina manufacturing sites.
Novo Nordisk plans a U.S. Launch in early January 2026, including an indication to reduce major adverse cardiovascular events, while pricing and demand remain key market factors.
Facing competition from Eli Lilly, Novo Nordisk struggles to regain share as more patients choose Zepbound, while it argues a convenient GLP-1 pill without cold storage could boost interest but unclear if market share will rise.

Report an issue with this summary

See Hide headlines from Center sources 111 sources

Key points from the Right

The U.S. Food and Drug Administration approved Novo Nordisk's Wegovy pill, which contains 25 mg of semaglutide, for chronic weight management on December 22, 2025.
In the OASIS 4 trial, participants taking the 25 mg Wegovy pill lost an average of 16.6% of their body weight, significantly more than the 2.7% loss in the placebo group.
Novo Nordisk anticipates launching the Wegovy pill in the U.S. In early January 2026, expanding treatment options for adults with obesity or overweight and related health conditions.
The approval expands treatment options for adults with obesity or overweight, potentially benefiting millions of patients and addressing rising healthcare costs.

Report an issue with this summary

Other (sources without bias rating):

See Hide headlines from Other sources 71 sources

Powered by Ground News™

Sources

CNN
Novo Nordisk